Ongoing phase III clinical trials, such as BREAKWATER, should aim to incorporate broader genetic profiling to further validate the superior sensitivity of patients with RNF43-mutant, MSS BRAFV600E CRC to anti-EGFR-/BRAFi-based therapies.
9 months ago
Journal • Tumor mutational burden
|
TMB (Tumor Mutational Burden) • RNF43 (Ring Finger Protein 43)